Page 7 - Thomas Theuringer News Today

QIAGEN leverages QuantiFERON-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also

Selection comes as part of an expansion in the DAX (Deutscher Aktienindex) to the 40 largest companies based on market capitalizationQIAGEN to join the DAX on September 20, 2021, the effective date for changes in index compositionQIAGEN to remain in TecDAX comprised of the 30 largest German technology sector compani...

(0) The therascreen KRAS RGQ PCR Kit receives U.S. regulatory approval from FDA for expanded scope to include use in guiding treatment with the newly approved therapy LUMAKRAS TM (sotorasib) from Amgen KRAS G12C mutation in NSCLC Test will be available under QIAGENs Day One Lab Readiness program QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit ( therascreen KRAS Ki...

QIAGEN N.V.: QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) QIAGEN is developing a tissue-based companion diagnosticin support of adagrasib, Miratis investigational selective KRAS G12C inhibitor Program adds to QIAGENs strong position in KRAS companion diagnostic testing in NSCLC QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) t...

(2) U.S. authorization gives healthcare professionals access to portable rapid testing device that can monitor immune status in relation to COVID-19 Test based on QIAGEN partner Ellumes proprietary eHub technology and helps ease testing shortfalls by using automation and providing easy-to-read results eHub digital device can handle eight tests at once, all working independently of each other, can process up to 32 samples per hour, can eventually be used simultaneously with the antigen test QIA...

(2) Q1 2021 net sales rise 52% (48% CER) to $567.2 million, exceeds outlook for at least 45% CER growth; adj. EPS up 94% to $0.66 ($0.65 CER), exceeds outlook for ~$0.60-0.62 CER 16% CER growth to $364 million from non-COVID product groups, represent 64% of total sales, while COVID-19 product group sales rise 186% CER to $203 million Q1 2021 operating cash flow rises over 700% to $128.6 million, free cash flow of $82.3 million Reaffirming full-year 2021 outlook for ~18-20% CER net sales grow...

QIAGEN N.V.: QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics Building on the success of EZ1 technology, three versions offer application area tailored value Integration with QIAsphere digital infrastructure allows for optimized lab productivity QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the upcoming launch of the EZ2 Connect product line, a next-level automated sample-processing platform whose simpl...

Message : Required fields DIASORIN, IN PARTNERSHIP WITH QIAGEN, LAUNCHES THE NEW LIAISON® LYMEDETECT® ASSAY BASED ON QUANTIFERON TECHNOLOGY IN COUNTRIES ACCEPTING CE MARK FOR EARLY DIAGNOSIS OF LYME BORRELIOSIS THE LIAISON® LYMEDETECT® ASSAY IS A SOLUTION FOR THE EARLY DIAGNOSIS OF LYME BORRELIOSIS COMBINING DETECTION OF IGG AND IGM ANTIBODIES AND CELLULAR IMMUNITY THE TEST IS AVAILABLE IN COUNTRIES ACCEPTING THE CE MARK AND IS DESIGNED TO BE RUN ON THE LIAISON®...

QIAGEN N.V.: QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity CE-IVD marking for Europe and other countries worldwide, EUA (Emergency Use Application) submission made in the U.S. Streamlined workflow cuts costs and plastic usage offering time to result of about two hours QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the artus SARS-CoV-2 Prep&Amp UM Kit which uses a liquid based sample ...

QIAGEN N.V.: QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance Kit supports analysis of over 6,000 samples simultaneously on highest-throughput sequencers Integrates with QIAGEN Digital Insights cloud solutions to support variant detection and reporting including clade and lineage annotations across sequencing platforms QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the launch of QIAseq DIRECT SARS-CoV-2 Kit...